Background: In functional gastrointestinal disorders a lack of objective biomarkers
| INTRODUC TI ON
A major challenge in functional gastrointestinal disorders has been to develop objective biomarkers that can be used to assess treatments more economically than symptoms, which typically show very wide variability. 1 Assessment of the small bowel and proximal colon has been particularly difficult owing to its inaccessibility. Capsule technologies, such as endoluminal image analysis 2 and pH monitoring, provide some information on motility and transit. Scintigraphy has been extensively used over the last three decades to show changes in transit through the different regions of the colon. 3 It has correctly predicted efficacy in a range of medications with different modes of action on bowel function. 4 It has shown acceleration of transit in constipation by stimulant laxatives such as bisacodyl 5 and secretogogues such as lubiprostone, 6 however, it cannot directly demonstrate whether any effects are due to changes in the balance of absorption/secretion of fluid from the lumen or changes in motility. 7 Transit has been shown to account for 19%-27% of the variance in stool form 3 indicating that there are other important parameters in predicting bowel function that may be measurable.
Up to 10 L/d of fluids move into, through and out of the gut lumen 8 but objectively measuring this is difficult and requires intestinal intubation which, as we and others have shown, alters fluid volumes significantly. 9 Disorders of fecal water content and/or bowel habit, either diarrhea or constipation, may result from an imbalance of secretion/absorption rather than just abnormal motor function.
Recently a number of new treatments for constipation stimulating intestinal water secretion have been introduced 10, 11 but assessment of the resulting changes in intestinal fluid content has not previously been possible.
We believe that this deficit could be corrected using MRI based methods to characterize the contents of patients' small bowel and colon, and to measure whole gut transit time as previously described. [12] [13] [14] [15] We have also used the relaxation times T1 and T2 to characterize luminal contents. 13, 16 T1 and T2 are the time constants with which the magnetization of material in the scanner returns to baseline after excitation by the radiofrequency pulse. They are sensitive to the physical and chemical environment of the water protons via interactions with surrounding molecules and in the context of colonic chyme, are expected to fall with a reduction in water associated with more solid chyme.
The aim of these studies was to assess the value of these MRI biomarkers by investigating their responsiveness to a wellcharacterized laxative, psyllium husk (ispaghula). Its water-holding properties are known to increase fecal water content and 24-hour fecal weight but reports of its effect on whole gut transit time are inconsistent. 17, 18 In some patients it produces unacceptable bloating but whether this reflects distension of intestinal lumen was uncertain.
We present two studies, investigating the MRI changes induced by psyllium in healthy volunteers, without constipation, and in patients with constipation. Our hypotheses were that MRI could detect an increase in small bowel water content caused by psyllium preventing water absorption. Furthermore, as this "trapped" water enters the colon, colonic water content would increase.
| MATERIAL S AND ME THODS

| Study design
Two studies were conducted: study 1, performed first, recruited adults without GI disorders (controls); study 2, using similar methodology (see below), recruited adults with chronic constipation (patients). Both were designed as placebo-controlled crossover studies and were conducted according to Good Clinical Practice as determined by the declaration of Helsinki. All authors had access to the study data, and reviewed and approved the final manuscript. The protocols were approved by institutional and national review boards, respectively, and prospectively registered on www.clinicaltrials.gov (NCT01805999 and NCT02144376). All subjects gave written informed consent.
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Key Points
• MRI can non-invasively simultaneously assess whole gut transit time, colonic volumes, and gut content including the composition of chyme, using the relaxation times T1
and T2.
• We show that the volume of the ascending colon and transverse colon is increased and the water content of the descending colon reduced in people with constipation compared to those with normal bowel habit
• MRI demonstrated that psyllium, an effective treatment for constipation, caused an increase in water in the small bowel, colonic volume and a newly identified marker of colonic contents, T1, which correlates with water content of stool.
• Through assessing multiple parameters contributing to constipation in a single test, MRI has the potential to provide clinical characterization of patients beyond transit alone, leading to more targeted application of current and novel therapies.
In study 1 three treatments were taken in random order: a placebo (maltodextrin) and two different doses of psyllium. Treatments were separated by washout periods of 1 week. Investigators were blind to the order of intervention. The patient study, study 2, was designed to be less burdensome and so used only two treatments:
placebo and high dose psyllium. In order to ensure return to baseline and avoid any carryover effect from previous treatment in the patient group, both treatment periods were preceded by ≥10 days of usual laxative use, then 8 days without laxatives other than rescue therapy. Rescue therapy (oral bisacodyl 5 mg) was permitted in patients who had not opened their bowels for 3 days and were experiencing distressing symptoms, but not in the 48 hours before MRI scans. 
| Study populations
| Treatments and procedures
The active treatment used was Metamucil ® Original Coarse Fiber (P&G, Cambridge, MA, USA), a powder containing approximately 3.5 g psyllium per 7 g product ( Figure 1 Blinding of subjects and investigators was ensured by providing the powders in opaque containers, labeled by independent staff and provided in sealed bags so they could not be recognized. The treatment allocation was according to a computer generated randomization code. Investigators were blind to the intervention.
Subjects were not told which intervention they were taking in any treatment period, although powders did differ subtly in appearance and texture.
In each treatment period subjects took the powder for 6 days.
Subjects measured out their doses using a plastic spoon and kept a diary of their treatment compliance. Compliance was also assessed by measurement of the total weight of powder consumed, expressed as a % of that expected if compliance was complete. Compliance of 60% was considered acceptable as >12 g psyllium daily would be expected to exert some effect. Subjects kept a daily diary of abdominal symptoms and bowel habit.
On the morning of treatment day 5, subjects swallowed five identical transit markers: cylinder-shaped inert capsules containing 0.4 mL 15 μM gadoteric acids, a positive MRI contrast agent.
15
Ingestion was confirmed in patients by direct observation or via a time-stamped video. On day 6 all subjects attended at 8am, fasted.
After an initial MRI scan, during which the intra-luminal position of the transit markers was documented, subjects consumed their morning dose followed by a 330 kcal standard rice pudding meal.
15,19
Scans were taken at hourly intervals for 7 hours. Doses of psyllium/ placebo were repeated 165 min and 320 min after the meal. A second 1000 kcal meal was consumed before the final scan. Subjects were scanned supine. Images were acquired using a 1.5 T scanner (Achieva, Philips Medical System, Best, the Netherlands). All MRI parameters were measured during a single 15 minute episode in the F I G U R E 1 Schematic of events during each treatment period. Each such period was separated by a washout period of at least 1 wk in the control study. In the patient study, subjects additionally recommenced usual laxative use for at least 10 d, followed by 8 d off laxatives prior to each study treatment scanner at each time point. Full details of the MRI methodology are given in the Data S1.
In the control study, fecal samples for measurement of stool water were taken at enrolment and after the final MRI scan of each treatment period. Patient samples were collected during the run-in period without laxatives before each treatment, and after at least 72 h of treatment. Bisacodyl rescue therapy was not permitted in the 48 hours prior to MRI scanning.
| Endpoints
All endpoints were MRI parameters unless reported otherwise. In the control study the primary endpoint was ascending colon free water content (ACWC). Secondary endpoints included: small bowel free water content (SBWC); colonic volume, defined as the sum of the segmental volumes of the ascending, transverse and descending colon (AC, TC, DC); the weighted average position score of the transit markers at 24 h (WAPS24). This was calculated using the formula (sum of the segment number X the number of markers in each segment divided by the total number of segments) as described previously 15 such that a higher score denotes slower whole gut transit.
Relaxation times (T1 and T2) of the chyme in the AC and DC were also measured. T1 (longitudinal relaxation time) depends upon the mobility of the water molecules as does T2 (transverse relaxation time) which also depends on exchange between water molecules and surrounding macromolecules. Therefore, both of these parameters are expected to decrease as the colonic content becomes more solid. Percentage fecal water content was also determined by freeze drying the stool. Symptoms of flatulence, bloating, abdominal pain, and diarrhea were monitored between MRI scans using 0-100 visual analogue scales. 20 In the patient study, the primary endpoint was the weighted average position score of the transit markers at 24 h (WAPS24).
Secondary endpoints included SBWC, ACWC, colonic volume, T1
and T2 of the colonic chyme, and percentage fecal water content.
Stool diaries were kept for the period off laxatives immediately before each treatment and during the treatment itself.
| Sample size and statistical analysis
Sample size calculation for the control study was based on pilot data in healthy volunteers from a previous study of ACWC. 13 Nine subjects would be required in a crossover design to detect an increase in postprandial area under the curve (AUC) of ACWC of 15 L.min (an increase in approximately 10%) with 90% power and P < .01. To allow for withdrawal and noncompliance, 16 subjects were recruited.
In the patient study the primary endpoint was WAPS24 since we had pilot data on this endpoint in a relevant patient group by which to power our study. We found, using our MRI marker method, a transit time of mean (SD) 69.2 (32.6) hours in IBS-C. 21 We calculated that a study with 20 subjects would have 80% power to detect a change in 21 hours or 30% which is similar to the changes previously reported in constipated subjects treated with psyllium 22, 23 and judged to represent a minimal clinically significant difference. 24 subjects were recruited to allow for attrition.
Fasting parameters were compared between treatments.
Postprandial endpoints were compared using AUC. Data are presented as median (interquartile range) or mean (±SD). Paired differences were assessed for normality using the Shapiro-Wilk test. 
| RE SULTS
The demographics of subjects are shown in the Data S1. 16 control subjects were randomized and completed the study. Of these, 10
showed adequate compliance. A scanner failure meant that data for one of these were not available so data from only nine subjects are presented. Thirty-seven patients consented, of whom 24 passed screening and were randomized. Four withdrew before scanning;
four more withdrew between treatment periods 1 and 2. Twenty patients had at least one MRI scan, completing one treatment period (11 psyllium; 9 placebo) and were included in the intention-to-treat analysis (ITT); 16 patients completed both treatment periods with appropriate compliance and were included in the paired analysis (Table S1 ). Fifteen met Rome III criteria for FC and 1 for IBS-C. Fasting and postprandial results are given in Tables 1 and 2 respectively.
| Outcomes assessed on fasting scans
On fasting scans, psyllium treatment did not lead to detectable differences from placebo (maltodextrin) in small bowel water content (SBWC) in either study (Table 1 ). In the ITT analysis of patients fasting SBWC was 33 mL (IQR 9-90) on placebo and 54 mL (24-77) on psyllium Figure 2A , B show fasting and postprandial SBWC for the paired data, Little ascending colon water content (ACWC) was detected with either treatment in either study: one control and one patient had >5 mL detectable on a fasting scan after 5 days of placebo compared to 4/9 (controls) and 4/18 (patients) with >5 mL detectable after 5 days of 7 g psyllium t.d.s. In controls, no differences in WAPS24 transit scores between treatments were detected as after 24 hours most markers had passed to the rectosigmoid or been expelled. In the patient study, however, where transit was the primary endpoint, scores tended to decrease, indicating faster transit.
In the ITT analysis WAPS24 fell from median 4.2 (3.2-5.3) on placebo to median 2.0 (1.5-4.0) after psyllium (P = .067). In the paired analysis (n = 16) there was a mean reduction in 0.8, 95% CI −0.2-1.7), a difference that was not statistically significant ( Figure 2C ). Figure 2D shows fasting colonic volumes for controls and patients. In controls, both psyllium doses increased fasting volume:
.s led to mean 53% increase (220 mL, 95% CI 127-312). In showed a significant increase in the fasting AC and transverse colon (TC), with a significant increase in the fasting descending colon (DC) also found in patients (Table 1 ). Figure 3 illustrates the Within-group comparison to maltodextrin *P < .05; **P < .01; ***P < .001. Between-groups comparison (controls vs patients) of maltodextrin results + P < .05, ++ P < .01. All comparisons to Maltodextrin *P < .05; **P < .01; ***P < .0005; ****P < .0001.
TA B L E 2
Comparisons by Wilcoxon signed rank test or paired t test.
changes in the ascending colon that were visible on anatomical scans and water content sequences.
Fasting data on T1 relaxation times, where higher values would be expected to reflect increased water content, are shown in Figure 4 . In controls, treatment tended to increase fasting T1 in the AC and DC ( Figure 4A ) but these differences were not significant in the ITT analysis. In patients, T1 DC was significantly higher in the DC after psyllium (590 ms, 446-1338) than placebo (213 ms, 176-420), P < .001. Within-individual comparisons of paired data found higher T1 values after psyllium in both AC (P < .05) and DC (P < .01). Fasting T2 measurements varied widely in controls without demonstrable difference while differences identified in patients were not consistent across ITT and paired analyses.
| Outcomes assessed on serial postprandial scans
Postprandial SBWC showed significant differences between treatments for both groups (Figure 2A,B) . A dose-response relationship was evident in controls, where postprandial AUC (change from baseline) psyllium 3.5 g t.d.s. led to an increase in postprandial SBWC compared to placebo (P < .01), albeit less pronounced than that seen with 7 g t.d.s. (P < .01 vs placebo) ( Table 2 ). An increase with treatment compared to placebo was equally apparent in patients:
median AUC for SBWC rose from 13.2 L.min (7.2-24.3) with placebo to 42.8 L.min (24-49.1) with psyllium (P < .05), with similar values seen in the paired analysis. In our previous work we described a fall in SBWC in the period 0-90 minutes after the test meal 19 but this did not occur with 7 g psyllium t.d.s. After the second meal of the study, between 360 and 420 minutes, a fall in SBWC was seen with all treatments in both studies.
Ascending colon water content (ACWC) in the control study,
where it was the designated primary endpoint, was significant greater in the postprandial phase after 7 g psyllium t.d.s. than placebo (P < .0001), with a clear dose-response relationship (P < .001, Table 2 ). In patients, postprandial ACWC was undetectable in most subjects taking placebo, with only 3 volumes >5 mL recorded at any point. In this group AUC for postprandial change in ACWC was greater with psyllium (P < .05) but highly variable, with mean postprandial ACWC ranging from 0-57 mL, equivalent to 5%-10% of colonic volume. Of note, postprandial colonic volumes did not change significantly from fasting baseline with any treatment in either study.
| Relaxation times T1 and T2
The AUC (change from baseline) for postprandial T1 AC was greater with psyllium in both regions in both groups (Table 2) . prandial T2 AC was higher after both psyllium doses than placebo in controls, and also higher after psyllium in patients in the paired analysis. Postprandial T2 DC was only found to be higher in patients on paired analysis (Table S1 ).
| Fecal water, bowel habit, and symptoms
In controls, stool % water content was not higher after placebo treatment than at baseline (baseline median 72%, IQR 69-73 vs 73%, 69-77 on placebo, P = NSig Wilcoxon). Stool % water was higher than baseline after both psyllium 3. (B and C), T1 of the ascending colon during a study day in B, controls; C, patients treated with placebo (maltodextrin 7 g), psyllium 3.5 g, or psyllium 7 g t.d.s. Ingestion of doses marked by an arrow ↓ P < .01, paired t test) but there was no change after placebo (mean decrease 0.2%, SD ± 10.0).
In the patient study stool frequency was similar during pretreatment periods off laxatives and while taking placebo, but higher while taking psyllium (P < .05 Wilcoxon, Figure 5A ). Mean (SD) stool form (Bristol Stool Form Scale) on psyllium was 3.5 (0.83) and 2.6 (1.3) on placebo (P = .07 Wilcoxon, Figure 5B ).
| Differences between controls and patients
Fasting scans showed a number of differences between controls and patients (Table 1) . WAPS24 scores were greater for patients than controls, indicating slower transit as expected ( Figure 2D ).
On placebo, fasting colon volumes were larger in patients than controls (median 745 mL, IQR 455-844 vs 372, 284-601 P < .05).
Differences were primarily due to larger AC and TC in patients.
Fasting T1 of chyme in both the AC and DC was shorter in patients than controls after placebo (both P < .05, Figure 4A ). After psyllium, values in patients approached those seen in controls on placebo.
Comparison of postprandial scans suggested differences be- 
| Correlation of relaxometry with fecal water and symptoms
Post hoc analysis of the combined data set for controls and patients showed a correlation between fecal water content and fasting T1 DC after placebo treatment ( Figure 6A ; Pearson's r = .65, P < .001 twotailed). Fasting T1 DC also correlated with stool frequency on treatment ( Figure 6B ; Pearson's r = .53, P < .05 two tailed).
Controls reported minimal symptoms during the study days. In patients, scores were also low, although fasting scores for bloating were higher after psyllium than placebo (median 5, 0-27 vs 1.5, 0-8, P < .05 Wilcoxon) and remained higher throughout the day.
| D ISCUSS I ON
By assessing baseline MRI parameters in healthy volunteers and in patients with constipation, and demonstrating their responsiveness to psyllium therapy, our study has not only demonstrated the value of MRI but also revealed some new findings about constipation. The clinical use of psyllium is based on its capacity to bind water, preventing absorption from the lumen. Consistent with this, postprandial small bowel water increased with psyllium in both patients and controls. It is worth noting that such a validated, non-invasive test may provide more representative data than older methods requiring aspiration of a non-absorbable marker as the aspiration catheter itself may stimulate intestinal activity, causing changes in absorption or secretion.
9,24
Volume measurements demonstrated the bulking effect of psyllium. The increases seen exceeded our expectations, in some cases doubling fasting colonic volume, which may explain the bloating that some patients experience. Similar substantial increases in colonic volumes as assessed by MRI have been recently reported in response to high fiber diets by others.
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By trapping water, the psyllium appears to abolish the immediate fall in SBWC caused by the rapid absorption of sucrose, glucose, and water we have previously observed using the same test meal. 19 The fall in SBWC after the second large 1000 kcal meal has been observed in most of our previous studies and we believe this reflects the gastro-ileal response to feeding as described previously.
26,27
We were unable to confirm an effect of psyllium on transit time although there was a numerical decrease in transit scores in constipated patients. These findings are consistent with other studies of psyllium where its effect on transit is small or non-significant. 17, 18, 22, 23 The increase in colonic volume offers an alternative explanation for how psyllium increases stool frequency since there is a greater mass of stool to pass. Total flow (mass/time) as assessed by daily stool output may, therefore, increase despite little change in speed through the gut (distance/time). Psyllium's main benefit may be through increased water content of colonic chyme and stool, making feces softer and hence easier to pass. Free water was more readily detected in the ascending colon of controls and in both groups after psyllium, but in individual patients it was often undetectable. This may have resulted from avid water absorption in the constipated colon, or mixing of free water into the colonic contents where the MRI signal of the water gets quickly reduced by interactions with bacteria and tiny pockets of gas from fermentation.
A major finding in this study was the demonstration of the value of T1 in assessing colon contents. This has not been previously reported. While free water was only detectable in a few cases, the pa- This will be of particular value in evaluating agents with novel modes of action like Tenapanor, 29, 30 an inhibitor of the sodium-proton exchanger NHE3, or plant derived inhibitors of aquaporins like rhein.
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Our study had limitations. Scanner failure and subject withdrawal reduced our numbers. Drop outs always raise the concern of selection so we report analysis of those 20 who completed the first arm of the cross-over as an ITT analysis. We also performed a paired analysis limited to those who completed the protocol and on whom we had adequate scans; supplementary data tables provide these results. Reassuringly we find very similar results in the paired analysis to the ITT analysis suggesting that drop out was random and not a source of bias. Sample sizes were hence small, limiting statistical confidence, but our data will enable more accurate power calculations for future studies. Heterogeneity in response and variation in dietary fiber intake may have obscured a treatment effect.
Comparisons between the studies may be affected by differences in age and gender since controls were younger and predominantly male, while patients were mainly female. In a previous study increased height was associated with larger colons, suggesting larger colons in men, although height-standardized colons in women were larger. 12 More data will be needed to understand the impact of age and gender compared to other physiological factors.
One advantage of the crossover designs used, and therefore reason to report both ITT and paired analyses, is the reduction in such sources of variation in assessment of an intervention's effect, Such There may have been other opportunities to introduce bias:
blinding was imperfect due to the nature of the intervention and compliance cannot not be guaranteed without direct observation. These issues are readily addressable with pharmaceutical therapies where plasma drug concentrations can be measured.
The objective nature of MRI outcomes somewhat mitigated these issues compared to other methods of assessing treatment efficacy particularly since MRI analysis was undertaken by a single operator (KAM) to reduce variation. Our previous work on intraobserver variation in colonic volume measurement found a coefficient of variation <5%. Fasting SBWC values were lower than we observed previously 13, 19 which may be a result of our small sample size here.
In a short scanning session we assessed fasting volume, relax- 
